A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer

Clinical Oncology

Volumn 11, Issue 3, 1999, Pages 174-178

  Mackay, H J ^a   Bissett, D ^b   Twelves, C ^a   Vasey, P A ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Breast neoplasms; Chemotherapy; Infusional 5 fluorouracil

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTINUOUS INFUSION; DIARRHEA; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN DISEASE; THROMBOSIS;

EID: 0032801125     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.1999.9036     Document Type: Article

References (16)

1. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-45.
2. Powles TJ, Smith IE. Medical management of breast cancer. London: Martin Dunitz 1991:139-51.
3. Lokich J, Bothe A, Fine N, et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981;48:2565-8.
4. Ng JSY, Cameron D, Leonard RCF. Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev 1994; 20:357-64.
5. Bissett D, Kaye SB, Baxter G, et al. Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy. Clin Oncol 1996;8:247-9.
6. Hayward JL, Carbone PP, Heuson J-C, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-8.
7. Hayward JL, Carbone PP, Heuson J-C, et al. Assessment of response to therapy in advanced breast cancer (an amendment). Br J Cancer 1977;38:201.
8. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed 15 years. Br J Cancer 1957;11:359-77.
9. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995;13:547-52.
10. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-52.
11. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
12. Gabra H, Cameron D, Lee LE, et al. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br J Cancer 1996;74:2008-12.
13. Jones AL, Smith IE, O'Brien M, et al. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatinum in patients with metastatic and locally advanced breast cancer: An active regime. J Clin Oncol 1994;12:1259-65.
14. Bonnfoi H, Smith IE, O'Brien M, et al. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer 1996;73:391-6.
15. Schueller J, Cassidy J, Reigner BG, et al. Tumour selectivity of XelodaTM in colorectal cancer patients. Proc ASCO 1997;16:227a(abstr 797).
16. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of Uracil and Tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-300.